MARKET

CTMX

CTMX

Cytomx Therapeutics Inc
NASDAQ
2.385
+0.005
+0.21%
After Hours: 2.420 +0.035 +1.47% 19:50 07/18 EDT
OPEN
2.420
PREV CLOSE
2.380
HIGH
2.500
LOW
2.380
VOLUME
676.08K
TURNOVER
--
52 WEEK HIGH
3.095
52 WEEK LOW
0.4000
MARKET CAP
375.74M
P/E (TTM)
4.966
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTMX last week (0707-0711)?
Weekly Report · 5d ago
Weekly Report: what happened at CTMX last week (0630-0704)?
Weekly Report · 07/07 09:15
Weekly Report: what happened at CTMX last week (0623-0627)?
Weekly Report · 06/30 09:15
Weekly Report: what happened at CTMX last week (0616-0620)?
Weekly Report · 06/23 09:14
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
Simply Wall St · 06/18 10:42
Weekly Report: what happened at CTMX last week (0609-0613)?
Weekly Report · 06/16 09:15
CytomX Therapeutics Approves Key Amendments at Annual Meeting
TipRanks · 06/13 20:33
Weekly Report: what happened at CTMX last week (0602-0606)?
Weekly Report · 06/09 09:15
More
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

Webull offers CytomX Therapeutics Inc stock information, including NASDAQ: CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.